New Monoclonal Antibody (mAB) Infusion Treatment Available for Recently Diagnosed, High-Risk COVID-19 Outpatients

The FDA recently approved the Emergency Use Authorization for a therapy consisting of monoclonal antibody for the treatment of coronavirus disease 2019 (COVID-19).

Q: What is a monoclonal therapy?

A: Monoclonal antibody therapy is an investigational medicine used for the treatment of COVID-19 in non-hospitalized adults and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization. Monoclonal antibody therapy is investigational because it is still being studied. There is limited information known about the safety or effectiveness of using monoclonal antibodies to treat people with COVID-19.

Q: What is an Emergency Use Authorization (EUA)?

A: The United States FDA has made monoclonal antibody infusions available under an emergency access mechanism called an EUA. An EUA means that the drugs have not undergone the same type of review as an FDA-approved product, because the FDA approval process takes a long time. COVID-19 is a national crisis, and we do not have the luxury of the years it takes to go through an FDA approval process. An EUA is a shorter, simpler review process that is not as thorough as the approval process.

To achieve EUA status, monoclonal antibody infusions have given investigators and the FDA reason to believe that the products may be effective in the treatment of COVID-19, and they currently meet the threshold for safety, performance and labeling.

Q: Who can receive this medication?

A: Adult patients with mild to moderate COVID-19. monoclonal antibody therapy should be administered as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset.

High risk is defined as patients meeting at least one of the following criteria, who:

- Have a body mass index (BMI) ≥ 35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥ 65 years of age
- Are ≥ 55 years of age **AND** have cardiovascular disease, **OR** hypertension, **OR**, chronic obstructive pulmonary disease/ other chronic respiratory diseases.

Q: What should I tell my health care provider before I receive COVID-19 monoclonal therapy?

A: Please tell your health care provider about all of your medical conditions, including if you:

- Have any allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illnesses
- Are taking any medications (prescription, over-the-counter, vitamins, and herbal products)

HOUSTON Methodist®
LEADING MEDICINE

New Monoclonal Antibody (mAB) Infusion Treatment Available for Recently Diagnosed, High-Risk COVID-19 Outpatients

Q: How will I receive the COVID-19 monoclonal antibody therapy?

A: Monoclonal antibody therapy is given to you through a vein (intravenous or IV) for at least 1 hour in an outpatient infusion center. You will receive one dose of monoclonal antibody therapy by IV infusion.

Q: What are the important possible side effects of COVID-19 monoclonal antibody therapy?

A: One possible side effect of monoclonal antibody therapy is an allergic reaction. Allergic reactions can happen during and after infusion with monoclonal antibody therapy such as Bamlanivimab. Tell your health care provider right away if you get any of the following signs and symptoms of allergic reactions: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.

The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site. These are not all the possible side effects of COVID-19 monoclonal antibody therapy. Not a lot of people have been given COVID-19 monoclonal antibody therapy.

Serious and unexpected side effects may happen. COVID-19 monoclonal antibody therapy is still being studied, so it is possible that all of the risks are not known at this time.

Q: What other treatment choices are there?

A: The FDA may allow for the emergency use of other monoclonal antibody therapy like Bamlanivimab, to treat people with COVID-19. Visit covid19treatmentguidelines.nih.gov for information on the emergency use of other medicines that are not approved by FDA to treat people with COVID-19. Your health care provider may talk with you about clinical trials for which you may be eligible.

It is your choice to be treated or not to be treated with COVID-19 monoclonal antibody therapy. Should you decide not to receive the COVID-19 monoclonal antibody therapy or stop it at any time, it will not change your standard medical care.

Q: How can I learn more?

- Ask your health care provider
- Visit **covid19treatmentguidelines.nih.gov**
- Contact your local or state public health department

HOUSTON Methodist®
LEADING MEDICINE

To see if you qualify, please call **346.356.3232**